Amgen Inc. has announced the initiation of early-stage clinical trials for a novel class of therapeutic molecules known as LOCKTACs. One such investigational medicine, AMG 193, is being tested as a potential first-in-class selective inhibitor of the enzyme PRMT5 for treating solid tumors lacking the MTAP gene. This trial aims to assess the efficacy of AMG 193 in stabilizing the interaction between PRMT5 and MTA, a natural metabolite, to inhibit tumor growth in MTAP-deleted cancer cells while minimizing toxicity to normal cells. The results of these trials have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on August 21, 2025, and is solely responsible for the information contained therein.